Investments
180Portfolio Exits
47Funds
2Expert Collections containing Casdin Capital
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Casdin Capital in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing Casdin Capital
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Casdin Capital in 4 CB Insights research briefs, most recently on Feb 16, 2021.


May 20, 2020
Here Are Q1’s Most Active Healthcare InvestorsLatest Casdin Capital News
May 11, 2022
Invetx , a Boston, MA-based pioneer in protein-based therapeutics for animal health, raised $60.5m in Series B financing. The round was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. The company intends to use the funds to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats. Led by Juergen Horn, PhD, chief executive officer, Invetx has built an integrated, iscovery, development, and manufacturing platform to create fully species-specific, optimized and half-life extended product candidates. By leveraging validated biotechnologies from human health and optimizing them for application in veterinary medicine, the company can generate differentiated antibodies to treat a wide variety of chronic and serious diseases in animals. Invetx has a broad pipeline of biotherapeutics in various therapeutic areas and expects to advance multiple candidates in development with product approvals anticipated potentially as early as 2025. In addition, the company has established a discovery, development, and commercialization partnership with Boehringer Ingelheim to pursue novel programs in addition to its own product portfolio. Invetx has also expanded its collaborations with AbCellera, Twist Bioscience and Wuxi Biologics. FinSMEs 10/05/2022
Casdin Capital Investments
180 Investments
Casdin Capital has made 180 investments. Their latest investment was in Character Biosciences as part of their Series A on May 5, 2022.
Casdin Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/17/2022 | Series A | Character Biosciences | $18M | Yes | 2 | |
5/17/2022 | Series B | Remix Therapeutics | $70M | Yes | 5 | |
5/10/2022 | Series B | MOMA Therapeutics | $150M | No | 7 | |
4/11/2022 | Series B | |||||
3/24/2022 | Series B |
Date | 5/17/2022 | 5/17/2022 | 5/10/2022 | 4/11/2022 | 3/24/2022 |
---|---|---|---|---|---|
Round | Series A | Series B | Series B | Series B | Series B |
Company | Character Biosciences | Remix Therapeutics | MOMA Therapeutics | ||
Amount | $18M | $70M | $150M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 2 | 5 | 7 |
Casdin Capital Portfolio Exits
47 Portfolio Exits
Casdin Capital has 47 portfolio exits. Their latest portfolio exit was Amunix on December 21, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/21/2021 | Acquired | 10 | |||
12/10/2021 | IPO | 1 | |||
11/1/2021 | IPO | 18 | |||
Casdin Capital Fund History
2 Fund Histories
Casdin Capital has 2 funds, including Casdin Private Growth Equity Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
11/9/2020 | Casdin Private Growth Equity Fund | $179M | 1 | ||
2/28/2018 | Casdin Venture Opportunities Fund |
Closing Date | 11/9/2020 | 2/28/2018 |
---|---|---|
Fund | Casdin Private Growth Equity Fund | Casdin Venture Opportunities Fund |
Fund Type | ||
Status | ||
Amount | $179M | |
Sources | 1 |
Casdin Capital Team
1 Team Member
Casdin Capital has 1 team member, including current Founder, Chief Investment Officer, Eli Casdin.
Name | Work History | Title | Status |
---|---|---|---|
Eli Casdin | AllianceBernstein, Bear Stearns, and Cooper Hill Partners | Founder, Chief Investment Officer | Current |
Name | Eli Casdin |
---|---|
Work History | AllianceBernstein, Bear Stearns, and Cooper Hill Partners |
Title | Founder, Chief Investment Officer |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.